肺癌及卵巢癌潜力靶点SLC34A2/NaPi2b相关蛋白抗体，12月14日欧盟委员会（EC）将Mersana的NaPi2b ADC药物upifitamab rilsodotin（UpRi）指定为治疗卵巢癌的孤儿药。NaPi2b靶点在肺癌及卵巢癌中发挥了重要作用。

名称：肺癌及卵巢癌潜力靶点SLC34A2/NaPi2b相关蛋白抗体

别名：NaPi2b,Sodium/phosphate cotransporter 2B, Na(+)-dependent phosphate cotransporter 2B, Na(+)/Pi cotransporter 2B, Sodium-dependent phosphate transport protein 2B, NaPi3b, NaPi-2b, SLC34A2, Solute carrier family 34 member 2, Sodium-phosphate transport protein 2B，SLC34A2蛋白抗体，NaPi2b蛋白抗体。

链接：https://www.antibodysystem.com/index/search?wd=SLC34A2%2FNaPi2b

相关蛋白抗体：

Anti-Human SLC34A2/NaPi2b Polyclonal Antibody (PHB65401)

Recombinant Human SLC34A2/NaPi2b Protein, N-His-SUMO (YHB65403)

Anti-Human SLC34A2/NaPi2b Antibody (SAA0766) (FHB65410)

Recombinant Human SLC34A2/NaPi2b Protein, N-GST (YHB65402)

Research Grade Anti-Human SLC34A2/NaPi2b (XMT-1592) (DHB65403)

Recombinant Human SLC34A2/NaPi2b, N-His (YHB65401)

Anti-Human SLC34A2/ NaPi2b Polyclonal Antibody (PHB65402)

形式：Liquid

纯度：>95%-98%(SDS-PAGE & RP-HPLC)

Accession：O95436

优势：多种属多标签，高稳定性，高生物活性，高纯度

用途范围：仅用于科研

储存：Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.

AntibodySystem：

AntibodySystem是由法国ProteoGenix专家团队创立的科研试剂品牌，产品管线覆盖各种病毒研究蛋白/抗体质控品、Invivo功能性抗体，流式抗休、抗药药物靶点蛋白以及其他活性蛋白、PEG抗体，磷酸化抗体、抗DNA抗体、小分子抗体、RUO ELISA试剂盒、生物类似物。

佰乐博生物：佰乐博生物代理antibodysystem，ProteoGenix品牌，是亚洲区运营总代理商

产品购买联系方式：027-65279366 /18162686757

邮箱：biolab-reagents@atagenix.com

QQ：2663991332

参考文献：

SLC34A2 promotes cancer proliferation and cell cycle progression by targeting TMPRSS3 in colorectal cancer. PMID: 34929599

The role of SLC34A2 in intestinal phosphate absorption and phosphate homeostasis. PMID: 30343332

Knockdown of SLC34A2 inhibits cell proliferation, metastasis, and elevates chemosensitivity in glioma. PMID: 30592329

Characterization of SLC34A2 as a Potential Prognostic Marker of Oncological Diseases. PMID: 34944522

SLC34A2 simultaneously promotes papillary thyroid carcinoma growth and invasion through distinct mechanisms. PMID: 32005974

The SLC34A2-ROS-HIF-1-induced up-regulation of EZH2 expression promotes proliferation and chemo-resistance to apoptosis in colorectal cancer. PMID: 30038060

New insights in the genetic variant spectrum of SLC34A2 in pulmonary alveolar microlithiasis; a systematic review. PMID: 37259144

SLC34A2 Gene mutation of pulmonary alveolar microlithiasis: report of four cases and review of literatures. PMID: 23164546

Impaired phosphate transport in SLC34A2 variants in patients with pulmonary alveolar microlithiasis. PMID: 35443721

SLC34A2 promotes neuroblastoma cell stemness via enhancement of miR-25/Gsk3beta-mediated activation of Wnt/beta-catenin signaling. PMID: 30868061

SLC34A2 promotes cell proliferation by activating STX17-mediated autophagy in esophageal squamous cell carcinoma. PMID: 38720472

SLC34A2 Targets in Calcium/Phosphorus Homeostasis of Mammary Gland and Involvement in Development of Clinical Mastitis in Dairy Cows. PMID: 38731279

Knockdown of SLC34A2 Inhibits Hepatocellular Carcinoma Cell Proliferation and Invasion. PMID: 28281971

Constitutive depletion of Slc34a2/NaPi-IIb in rats causes perinatal mortality. PMID: 33846411

SLC34A2 regulates miR-25-Gsk3beta signaling pathway to affect tumor progression in gastric cancer stem cell-like cells. PMID: 29178392

Is SLC34A2 Associated With Concomitant Calcium Metabolism Disorder in Pulmonary Alveolar Microlithiasis (PAM)? PMID: 37217383

SLC34A2 Up-regulation And SLC4A4 Down-regulation Correlates With Invasion, Metastasis, And The MAPK Signaling Pathway In Papillary Thyroid Carcinomas. PMID: 34405007

Phosphate dysregulation via the XPR1-KIDINS220 protein complex is a therapeutic vulnerability in ovarian cancer. PMID: 35437317

Eight novel variants in the SLC34A2 gene in pulmonary alveolar microlithiasis. PMID: 31831582

SLC34A2 Regulates the Proliferation, Migration, and Invasion of Human Osteosarcoma Cells Through PTEN/PI3K/AKT Signaling. PMID: 28777670

CD74/SLC34A2-ROS1 Fusion Variants Involving the Transmembrane Region Predict Poor Response to Crizotinib in NSCLC Independent of TP53 Mutations. PMID: 38070598

Overexpression of SLC34A2 is an independent prognostic indicator in bladder cancer and its depletion suppresses tumor growth via decreasing c-Myc expression and transcriptional activity. PMID: 28151475

NaPi2b expression in a large surgical Non-Small Cell Lung Cancer (NSCLC) cohort. PMID: 34953676

Antibody-Drug Conjugates in Gynecologic Cancer. PMID: 37229642

(213)Bi/(211)At-Labeled MX35, an anti-sodium-dependent phosphate transport protein 2b (NaPi2b) murine monoclonal antibody. PMID: 22675742

Toward a Topology-Based Therapeutic Design of Membrane Proteins: Validation of NaPi2b Topology in Live Ovarian Cancer Cells. PMID: 35911971

Sodium-dependent phosphate transporter NaPi2b as a potential predictive marker for targeted therapy of ovarian cancer. PMID: 34504954

Development of potent non-acylhydrazone inhibitors of intestinal sodium-dependent phosphate transport protein 2b (NaPi2b). PMID: 35917765

Design, synthesis and biological evaluation of novel pyridine derivatives as gut-selective NaPi2b inhibitors. PMID: 35346844

Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability. PMID: 30158152

Discovery of Gut-Restricted Small-Molecule Inhibitors of Intestinal Sodium-Dependent Phosphate Transport Protein 2b (NaPi2b) for the Treatment of Hyperphosphatemia. PMID: 35034442

Development of monoclonal antibodies specific for the human sodium-dependent phosphate co-transporter NaPi2b. PMID: 18724815

Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer. PMID: 32534811

Immunohistochemical analysis of NaPi2b protein (MX35 antigen) expression and subcellular localization in human normal and cancer tissues. PMID: 21956469

The study of phosphate transporter NAPI2B expression in different histological types of epithelial ovarian cancer. PMID: 19300415

In silico analysis and immunohistochemical characterization of NaPi2b protein expression in ovarian carcinoma with monoclonal antibody Mx35. PMID: 22553815

Advances in antibody-drug conjugates for gynecologic malignancies. PMID: 36484278